Filing Flows › Nuo Therapeutics (AURX) › Q1 2025
Nuo Therapeutics (AURX) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 30, 2025
Nuo Therapeutics (AURX) reported revenue of $484K for the first quarter 2025 (Q1 2025), +106% from a year earlier and +23% from the quarter before. Operating margin was -153.8%, net loss $746K (154.0% of revenue).
Nuo Therapeutics, Q1 2025: revenue $484K (+106% year over year), operating margin -153.8%, net loss $746K, operating cash flow $2K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $484K | +23% | +106% |
| Operating profit | −$745K | — | — |
| Net earnings | −$746K | — | — |
| Operating cash flow | $2K | — | — |
What changed
Revenue was $484K in Q1 2025, up 106% year over year and up 23% from the previous quarter.
Gross margin was 75.0%, down 3.4 points from a year earlier. Operating costs exceeded revenue by $745K, an operating margin of -153.8%. Operating expenses grew 24% against revenue growth of 106%. The quarter ended with a net loss of $746K, wider than the previous quarter's $497K loss.
Operating cash flow was $2K. Non-cash charges added back $15K of depreciation and $19K of share-based compensation. Working capital and other items added $713K. Capital expenditures of $230K exceeded it, leaving free cash flow of −$228K.
Questions
What was Nuo Therapeutics' revenue in the first quarter 2025?
Nuo Therapeutics (AURX) reported revenue of $484K for the first quarter 2025 (Q1 2025), +106% from a year earlier and +23% from the quarter before.
Was Nuo Therapeutics profitable in the first quarter 2025?
Operating loss was $745K (-153.8% of revenue) and net loss $746K.
Source: Nuo Therapeutics 10-Q on SEC EDGAR.